CHRONIC MYELOID LEUKEMIA

This study tests whether combining two drugs, azacitidine and venetoclax, can help people with a high-risk form of chronic myelomonocytic leukemia (CMML). The trial enrolled 44 adults and is currently active but not recruiting. The goal is to see how well the combination works an…

This study looks at whether the drug nilotinib can help people with chronic myeloid leukemia (CML) stay in remission after stopping their usual treatment for a second or third time. About 75 adults who previously tried and failed to stop TKI therapy will take nilotinib for at lea…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor for people with blood cancers like leukemia and lymphoma. The goal was to see how many patients survived and had successful engraftment by 100 days and one year after transp…

This study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly versus slowly reducing the dose over a year before stopping. The goal i…

This study looks at whether reducing the dose of the drug olverembatinib can still keep chronic myeloid leukemia (CML) under control in patients who have already responded well to treatment. About 100 adults with CML in chronic or accelerated phase will take a lower dose (20 mg e…

This study is testing whether some patients with a type of leukemia called CML, who have been in a very deep remission for years while taking daily TKI pills, can safely stop taking those pills and stay in remission. Researchers will monitor 100 patients closely after they stop t…

This study tests a new way to do stem cell transplants using cells from a half-matched family donor. By removing certain immune cells before transplant, researchers hope to lower the risk of graft-versus-host disease, a serious complication. The goal is to help patients with bloo…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 3…

This study follows 201 adults with chronic myeloid leukemia who are taking the drug asciminib as a third or later treatment option. Researchers want to see how many patients stay on the drug after 12 months and how well it controls the disease in everyday medical practice. The go…

This study looks at how blood cancers and stem cell transplants impact muscle function in 144 patients. Researchers want to see if muscle problems can help predict complications like infections, hospital stays, or survival. The goal is to better understand recovery and guide futu…